Comparison of tailored eradication versus modified bismuth quadruple therapy in Korea: a randomized controlled trial.
Objectives: We aimed to compare the success rate, adverse drug events, and cost-effectiveness of tailored Helicobacter pylori eradication and modified bismuth-containing quadruple therapy.Methods: The diagnosis of H. pylori infection was randomly based on either rapid urease test (RUT) or dual primi...
| Publicado en: | Expert Review of Anti-infective Therapy Vol. 20; no. 6; pp. 923 - 930 |
|---|---|
| Autores principales: | , , |
| Formato: | research randomized controlled trial Journal Article |
| Publicado: |
Taylor & Francis Ltd
Jun2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=157107924&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 157107924 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 14787210 1IHP jtl: Expert Review of Anti-infective Therapy issn: 14787210 maglogo: N pubinfo: dt: Jun2022 vid: 20 iid: 6 pid: 377 pub: Taylor & Francis Ltd place: Philadelphia, Pennsylvania artinfo: ui: 157107924 157107924 NLM34883037 157107924 10.1080/14787210.2022.2017280 NLM34883037 157107924 ppf: 923 ppct: 7 formats: tig: atl: Comparison of tailored eradication versus modified bismuth quadruple therapy in Korea: a randomized controlled trial. aug: au: Cho, Jun-Hyung Jin, So Young Park, Suyeon affil: Digestive Disease Center, Soonchunhyang University Hospital, Seoul, Korea sug: subj: Helicobacter Infections Drug Therapy Helicobacter Pylori Treatment Outcomes Clarithromycin Therapeutic Use Metronidazole South Korea Bismuth Drug Therapy, Combination Human Amoxicillin Antibiotics Adverse Effects Comparative Studies Multicenter Studies Randomized Controlled Trials Evaluation Research Validation Studies Scales ab: Objectives: We aimed to compare the success rate, adverse drug events, and cost-effectiveness of tailored Helicobacter pylori eradication and modified bismuth-containing quadruple therapy.Methods: The diagnosis of H. pylori infection was randomly based on either rapid urease test (RUT) or dual priming oligonucleotide (DPO)-based multiplex polymerase chain reaction (PCR) in 1:1 ratio. According to the presence of point mutations that cause clarithromycin resistance, patients in the tailored therapy (TT) group received standard triple therapy or classic bismuth quadruple therapy. Patients with positive RUT results received 40 mg pantoprazole, 1000 mg amoxicillin, 750 mg metronidazole, and 600 mg bismuth subcitrate twice daily for 14 days (PAM-B therapy).Results: Between the TT (n = 141) and PAM-B groups (n = 141), H. pylori eradication rate did not differ significantly according to intention-to-treat (TT: 80.9% vs. PAM-B: 85.8%, P = 0.262), modified intention-to-treat (TT: 89.1% vs. PAM-B: 91.0%, P = 0.606), and per-protocol (TT: 89.0% vs. PAM-B: 93.5%, P = 0.198) analyses. The average cost for successful eradication was higher in the TT group than in the PAM-B group ($340.7 vs. $263.9 per patient).Conclusion: PAM-B therapy exhibits similar efficacy and improved cost-effectiveness compared to TT based on the results of DPO-PCR tests.Clinical Trial Registration: www.clinicaltrials.gov identifier is NCT05002595. pubtype: Academic Journal doctype: research randomized controlled trial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|